Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV versus Engerix-B and Fendrix in previously vaccinated non-seroprotected adults on hemodialysis
2010-019633-10Phase 3Completed
- Sponsor
- Dynavax Technologies
- Start
- Jul 2010
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Heplisav-B and Hepatitis B vaccine in hepatitis B (HBV) (3 arms), sponsored by Dynavax Technologies. Primary endpoint: Seroprotection rate at Week 4. Started Jul 2010; status: completed.
02
Drugs
Heplisav-BHepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2010-019633-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019633-10.